Editorial: Drug monitoring targets for optimising adalimumab in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 7, 2014, Pages 854-855

  Swoger, J M ^a   Levesque, B G ^b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DRUG ANTIBODY; ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MONITORING; EDITORIAL; HUMAN; MINIMUM PLASMA CONCENTRATION; REMISSION; BLOOD; FEMALE; MALE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; MALE;

EID: 84908090100     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12911     Document Type: Editorial

References (5)

1. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014; 39: 1126-35.
2. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
3. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40: 620-8.
4. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24.
5. A randomized evaluation of health costs and resource utilization comparing testing-based therapy to empiric dose intensification for the management of inflammatory bowel disease. NCT01960426